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ABSTRACT
Objectives: The objective of this work is to synthesize new pyrimidine derivatives starting from ethyl 2,4-dioxo-4-(thiophen-2-yl)butanoate. 
Several oxadiazole, triazole, and thiadiazole moieties were incorporated into the pyrimidine backbone. The structure of the novel compounds was 
characterized by elemental analysis and spectroscopic methods.
Methods: Synthesis of the target compounds was materialized starting from 2-oxo-6-(thiophen-2-yl)-2,3-dihydropyrimidine-4-carbohydrazide (4) 
which was prepared from the appropriate ethyl 2-oxo-6-(thiophen-2-yl)-2,3-dihydropyrimidine-4-carboxylate (2). Several synthetic pathways were 
used for the preparation of the targets. Some of the newly synthesized compounds were subjected to in vitro cytotoxic screening against breast 
carcinoma and colon carcinoma cell lines. On the other hand, the antimicrobial activity evaluation of some newly prepared compounds was performed 
using cup plate diffusion method.
Results: It was observed that the oxadiazole derivative 7b was the most potent compound against breast carcinoma cell line (IC50=7.6 μg/ml). However, 
pyrimidine carrying substituted 1,2,4-triazole-2-thione moiety at position 6, 11 showed the highest cytotoxic activity against colon carcinoma cell 
line (IC50=4.7 μg/ml). On the other hand, compound 5c was the most active broad spectrum antimicrobial agent against the chosen microbial strains.
Conclusion: From the observed results, further investigations recommended for the synthesis of heterocycles incorporated to pyrimidine backbone 
as cytotoxic as well as broad spectrum antimicrobial agents.
Keywords: Pyrimidine, Oxadiazole, Triazole, Thiadiazole, In vitro anticancer study, Antimicrobial study.
INTRODUCTION
The pyrimidine moiety is a versatile lead molecule in pharmaceutical 
development because of their diverse chemical reactivity, accessibility 
and a wide range of biological activities. In the past few years, the 
therapeutic interest of pyrimidine derivatives in pharmaceutical 
and medical fields has been given a great attention to the medicinal 
chemists. Literature survey revealed that pyrimidine derivatives 
are well-known to have antimicrobial [1-3], anti-malarial [4], anti-
tubercular [5], anti-inflammatory [6], analgesic [7], anticonvulsant [8], 
and anticancer [9-13] activities.
Furthermore, it is evident from literature that thiophene derivatives 
are known to be associated with broad spectrum biological activity, 
including antimicrobial [14-16] and cytotoxic activities [17-20].
In addition, heterocycles bearing symmetrical triazole moiety were 
reported to show a wide range of biological activities [21-25]. Moreover, 
antimicrobial [26], antifungal [27], anticancer [28,29] as well as 
antioxidant [30] activities were reviewed. Moreover, 1,3,4-oxadiazole 
nucleus exhibited interesting biological properties such as 
antimicrobial [31], antifungal [32], and antioxidant [33] activities. 
Likewise, different substituted 1,3,4-thiadiazoles were reported to have 
anticancer [34] and antimicrobial [35] activities.
In the brightness of the previous literature survey, and in concurrence 
with our objective, our attempts were aimed to synthesize a novel 
series of pyrimidine derivatives incorporated with an assortment of 
ring systems such as thiophene, triazole, oxadiazole, and thiadiazole. 
The synthesized products were evaluated for their cytotoxicity 
and antimicrobial activity, hoping to obtain potent anticancer and 
antimicrobial effects.
METHODS
Melting points were determined on a Griffin apparatus and are 
uncorrected. Infrared (IR) spectra were determined as KBr discs on 
Shimadzu Fourier transform IR 8000 spectrophotometer (Japan). 
1HNMR, 13CNMR spectra were carried out on Varian Gemini 300 MHz 
and 75 MHz spectrophotometer (Switzerland) using TMS as internal 
standard and DMSO-d6 as a solvent. Mass spectra were run on Hewlett 
Packard 5988 spectrometer Microanalytical Center, Cairo University, 
Egypt. Elemental analysis was carried out using VARIO EL ELEMENTAR 
Apparatus at the Regional Center for Mycology and Biotechnology, Al-
Azhar University Campus, Nasr City, Cairo, Egypt. The progress of the 
reaction was monitored by thin layer chromatography (TLC) using 
TLC sheets precoated with UV fluorescent silica gel Merk 60 F254 and 
spots were visualized by iodine vapor or irradiation with UV lamp. 
MCF-7 breast cancer and HCT-116 colon cancer cell lines were obtained 
from the Regional Center for Mycology and Biotechnology, Al-Azhar 
University Campus, Nasr City, Cairo, Egypt. The used bacterial and 
fungal cultures were obtained from Microbiology Department, Faculty 
of Pharmacy, Zagazig University, Egypt. Compound 1 was synthesized 
according to the reported method [36].
Synthesis of ethyl 2-hydroxy-6-(thiophen-2-yl)pyrimidine-4-
carboxylate (2)
Compound 1 (0.45 g, 2 mmol) and urea (0.12 g, 2 mmol) were dissolved 
in ethanol (15 ml) and conc. HCl (2 ml) was added. The reaction mixture 
was heated under reflux for 72 hrs. After cooling, the solid product 
was collected and crystallized from ethanol to give greenish white 
crystals. Yield 84%; m.p. 215-217°C; IR (KBr; cm−1): 3451 (OH), 3100 
(CH aromatic), 2992, 2919 (CH aliphatic), 1739 (C=O), 1622 (C=N), 
1523 (C=C); 1HNMR (DMSO-d6, 300 MHz) d: 1.36 (t, J=7.2 Hz, 3H, CH3), 
4.33-4.40 (q, J=7.2 Hz, 2H, CH2), 6.70-8.19 (m, 4H, Ar-H), 7.24-8.19 (m, 
Research Article
Asian J Pharm Clin Res, Vol 9, Issue 2, 2016, 306-313
 ABD EL-AAL et al. 
307
3H, Ar-H), 12.01 (s, 1H, OH exchangeable with D2O); m/z: 250 (M+), 
208 (23.61), 178 (100); Elemental analysis (%): Calcd. for: C11H10N2O3S 
(250.04): C, 52.79; H, 4.03; N, 11.19, found: C, 52.91; H, 4.11; N, 11.37.
General procedure for the synthesis of compounds (3a, b)
Compound 2 (0.5 g, 2 mmol), appropriate alkyl halide (2 mmol) in 
dimethyl formamide (DMF) (4 ml) containing K2CO3 (0.276 g, 2 mmol) 
were stirred at room temperature 24 hrs. The solution was quenched 
with ice, filtered. The separated solid was crystallized from ethanol as 
yellow crystals.
Synthesis of ethyl 3-methyl-2-oxo-6-(thiophen-2-yl)-2,3-
dihydropyrimidine-4-carboxylate (3a)
Yield 69%; m.p. 240-242°C; IR (KBr, cm–1): 3093 (CH aromatic), 2995, 
2958 (CH aliphatic), 1737 (C=O, ester), 1652 (C=O, pyrimidine), 1607 
(C=N), 1580 (C=C); 1HNMR (DMSO-d6, 300 MHz) d: 1.35 (t, J=7.2 Hz, 3H, 
CH3), 3.32 (s, 3H, N-CH3), 4.38-4.40 (q, J=7.2 Hz, 2H, O-CH2), 6.76 (s, 1H, 
pyrimidine-H), 7.27-8.24 (m, 3H, thiophene-H); elemental analysis (%): 
Calcd. for C12H12N2O3S (264.30): C, 54.53; H, 4.58; N, 10.60, found: C, 
54.67; H, 4.66; N, 10.74.
Synthesis of ethyl 3-butyl-2-oxo-6-(thiophen-2-yl)-2,3-
dihydropyrimidine-4-carboxylate (3b)
Yield 65%, m.p. 130-132°C; IR (KBr, cm–1): 3083 (CH aromatic), 2962, 
2932, 2870 (CH aliphatic), 1745 (C=O, ester), 1655 (C=O, pyrimidine), 
1575 (C=N), 1543 (C=C); 1HNMR (DMSO-d6) d: 0.97 (t, 3H, CH3, 
butyl), 1.35 (t, 3H, CH3, ester), 1.42-1.77 (m, 4H, 2CH2, butyl), 3.31 
(t, 2H, N-CH2), 4.38 (q, 2H, O-CH2), 7.26-8.23 (m, 4H, Ar-H); m/z (%): 
306.10 (20.02) (M+), 232.05 (82.48 ), 134.05 (100). Elemental analysis 
(%): Calcd. for C15H18N2O3S (306.38): C, 58.80; H, 5.92; N, 9.14, Found: 
C, 58.93; H, 5.98; N, 9.21.
Synthesis of 2-hydroxy-6-(thiophen-2-yl)pyrimidine-4-
carbohydrazide (4)
A mixture of compound 2 (0.5 g, 2 mmol) and hydrazine hydrate (98%) 
(0.1 g, 2 mmol) in ethanol (10 ml) was heated under reflux for 5 hrs. 
Excess ethanol was evaporated then the separated solid was filtered, 
washed with ethanol and crystallized from acetic acid to give yellow 
crystals.
Yield 55%; m.p.281-283°C; IR (KBr; cm–1): 3421 (OH), 3312, 3302 
(NH, NH2), 3097 (CH aromatic), 1660 (C=O), 1607 (C=N), 1532 (C=C); 
1HNMR (DMSO-d6, 300 MHz) d: 4.35 (s, 2H, NH2 exchangeable with 
D2O), 7.27-8.09 (m, 4H, Ar-H), 9.90 (s, 1H, NH exchangeable with D2O), 
12.25 (s, 1H, OH exchangeable with D2O); 13CNMR (DMSO-75 MHz): 
101, 129, 03, 130.45, 132.61, 140.87, 160.5; m/z (%): 236 (85.05) (M+), 
178 (100), 134 (75.88); elemental analysis (%): Calcd. for C9H8N4O2S 
(236.25): C, 45.75; H, 3.41; N, 23.72, found: C, 45.88; H, 3.39; N, 23.98.
General procedure for the synthesis of compounds 5a-g
A mixture of compound 4 (0.47 g, 2 mmol) and the appropriate 
aromatic aldehyde (2 mmol) in glacial acetic acid (15 ml) was heated 
under reflux for 6 hrs. After cooling and dilution with water, the solid 
product was collected and crystallized from acetic acid.
Synthesis of N’-benzylidene-2-hydroxy-6-(thiophen-2-yl) 
pyrimidine-4-carbohydrazide (5a)
Yield (53%); m.p. 290-292°C; IR (KBr; cm–1): 3444 (OH), 3261 (NH), 
3085 (CH aromatic), 1655 (C=O), 1639(C=N), 1603(C=C); 1HNMR 
(DMSO-d6, 300 MHz) d: 7.27-8.19 (m, 9H, Ar-H), 8.59 (s, 1H, N=CH), 
12.04 (s, 1H, NH exchangeable with D2O), 12.31 (s, 1H, OH exchangeable 
with D2O); m/z (%): 323.95 (2.54) (M+), 220.9 (65.57), 178 (100); 
Elemental analysis (%): Calcd. for C16H12N4O2S (324.07): C, 59.25; H, 
3.73; N, 17.27, Found: C, 59.43; H, 3.76; N, 17.35.
Synthesis of 2-hydroxy-N’-(4-methoxybenzylidene)-6-(thiophen-
2-yl) pyrimidine-4-carbohydrazide (5b)
Yield 78%; m.p. 280-282°C; IR (KBr; cm–1): 3486 (OH), 3363(NH), 
3085, 3033 (CH aromatic), 1698 (C=O), 1595 (C=N), 1554 (C=C); 
1HNMR (DMSO-d6) d: 3.81 (s, 3H, OCH3), 7.01-8.17 (m, 8H, Ar-H), 8.51 
(s, 1H, N=CH), 11.89 (s, 1H, NH exchangeable with D2O), 12.25 (s, 1H, 
OH exchangeable with D2O); m/z (%): 354 (12.54) (M+), 221 (96.05), 
178 (100); Elemental analysis (%): Calcd. for C17H14N4O3S (354.38): 
C, 57.62; H, 3.98; N, 15.81, Found: C, 57.81; H, 4.03; N, 15.92.
Synthesis of 2-hydroxy-N’-(4-hydroxybenzylidene)-6-(thiophen-2-
yl)pyrimidine-4-carbohydrazide (5c)
Yield 70%; m.p. 315-317°C; IR (KBr; cm−1): 3439 (2OH), 3221 (NH), 
3090 (CH aromatic), 1656 (C=O), 1597 (C=N), 1511 (C=C); 1HNMR 
(DMSO-d6, 300 MHz) d: 6.87-8.17 (m, 8H, Ar-H), 8.46 (s, 1H, N=CH), 9.99 
(s, 1H, p-OH exchangeable with D2O), 11.83 (s, 1H, NH, exchangeable 
with D2O), 12.25 (s, 1H, OH pyrimidine, exchangeable with D2O); m/z 
(%): 340 (8.41) (M+), 221 (61.81), 178 (100); Elemental analysis (%): 
Calcd. for C16H12N4O3S (340.06): C, 56.46; H, 3.55; N, 16.46, found: C, 
56.55; H, 3.59; N, 16.58.
Synthesis of 2-hydroxy-N’-(4-nitrobenzylidene)-6-(thiophen-2-yl) 
pyrimidine-4-carbohydrazide (5d)
Yield 85%, m.p. 300-302°C, IR (KBr; cm–1): 3434 (OH), 3191(NH), 
3027 (CH aromatic), 1663 (C=O), 1621 (C=N), 1567 (C=C), 1515,1339 
(NO2); 1HNMR (DMSO-d6, 300 MHz) d: 7.27-8.34 (m, 8H, Ar-H), 8.85 
(s, 1H, N=CH), 11.83 (s, 1H, NH exchangeable with D2O), 12.35 (s, 1H, 
OH exchangeable with D2O); m/z (%): 369 (1.62) (M+), 221 (44.99), 
178 (100); Elemental analysis (%): Calcd. for C16H11N5O4S (369.35): C, 
52.03; H, 3.00; N, 18.96, Found: C, 52.14; H, 3.01 N, 19.17.
Synthesis of 2-hydroxy-N’-(4-methylbenzylidene)-6-(thiophen-2-
yl) pyrimidine-4-carbohydrazide (5e)
Yield 78%; m.p. 275-277°C; IR (KBr; cm-1): 3482 (OH), 3242 (NH), 3086 
(CH aromatic), 2921, 2807 (CH aliphatic), 1685 (C=O), 1594 (C=N), 1558 
(C=C); 1HNMR (DMSO-d6, 300 MHz) d: 2.27 (s, 3H, CH3), 7.20-8.18 (m, 
8H, Ar-H), 8.54 (s, 1H, N=CH), 11.96 (s, 1H, NH exchangeable with D2O), 
12.23 (s, 1H, OH exchangeable with D2O); m/z (%): 338 (6.37) (M+), 
221 (84.54), 178 (100). Elemental analysis (%): Calcd for C17H14N4O2S 
(338.38): C, 60.34; H, 4.17; N, 16.56, found: C, 60.49; H, 4.24; N, 16.74.
Synthesis of N’-(4-chlorobenzylidene)-2-oxo-6-(thiophen-2-yl)-
2,3-dihydro-pyrimidine-4-carbohydrazide (5f)
Yield 82%; m.p. 267-269оC; IR (KBr; cm-1): 3384 (NH), 3212 (NH), 
3081 (CH aromatic), 1677 (C=O), 1645 (C=O), 1597 (C=N), 1559 
(C=C).1HNMR (DMSO-d6, 300 MHz) d: 7.25-8.59 (m, 8H, Ar-H), 8.70 (s, 
1H, N=CH), 10.47 (s, 1H, NH exchangeable with D2O), 12.39 (s, 1H, NH 
exchangeable with D2O); m/z (%): 360 (0.31) (M+ +2), 358 (0.61) (M+), 
278 (33.58), 236 (68.07), 178 (100). Elemental analysis (%): Calcd. for 




Yield 79%; m.p. 270-272°C; IR (KBr; cm-1); 3434 (OH), 3278 (NH), 
3086 (CH aromatic), 2985, 2936, 2837 (CH aliphatic), 1690 (C=O), 
1599 (C=N), 1575 (C=C); 1HNMR (DMSO-d6, 300 MHz) d: 3.72 
(s, 3H, p-OCH3), 3.84 (s, 6H, 2 m-OCH3), 7.03-8.18 (m, 6H, Ar-H), 8.49 
(s, 1H, N=CH), 12.02 (s, 1H, NH exchangeable with D2O), 12.31 (s, 1H, 
OH exchangeable with D2O); 13CNMR (DMSO-75 MHz): 55.90, 56.00, 
60.16, 104.62, 105.61, 115.22, 119.00, 129.11, 129.46, 130.45, 132.48, 
139.62, 140.22, 150.22, 153.22, 160.76, 161.23, 167.88, 173.73; m/z 
(%): 414 (45.96) (M+), 220 (32.24), 178 (100); Elemental analysis (%): 
Calcd. for C19H18N4O5S (414.44): C, 55.06; H, 4.38; N, 13.52, Found: C, 
55.13; H, 4.45; N, 13.61.
General procedure for the synthesis of (6a-c)
The appropriate acid chloride (2 mmol) and compound 4 (0.47 g, 
2 mmol) were heated under reflux in pyridine (5 ml) for 2 hrs. After 
cooling, the reaction mixture was then quenched with ice, acidified 
to litmus paper with glacial acetic acid and filtered. The product was 
crystallized from ethanol as yellow crystals.
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Yield 84%; m.p. 215-217°C; IR (KBr; cm−1): 3447 (OH), 3371 (NH), 
3109 (NH), 3031 (CH aromatic), 1659 (2C=O), 1601 (C=N), 1551 (C=C); 
1HNMR (DMSO-d6, 300 MHz) d: 7.27-8.16 (m, 9H, Ar-H), 10.80 (s, 1H, 
NH exchangeable with D2O), 10.82 (s, 1H, NH, exchangeable with D2O), 
12.36 (s, 1H, OH exchangeable with D2O); m/z (%): 340.10 (13.76) (M+), 
128 (5.09), 105.05 (100); Elemental analysis (%): Calcd. for C16H12N4O3S 
(340.36): C, 56.46; H, 3.55; N, 16.46. found: C, 56.62; H, 3.59; N, 16.63.
Synthesis of 2-hydroxy-N’-(4-methoxybenzoyl)-6-(thiophen-2-yl)
pyrimidine-4-carbohydrazide (6b)
Yield 80%; m.p. 200-202°C; IR (KBr; cm–1): 3450 (OH), 3370 (NH), 3287 
(NH), 3091 (CH aromatic), 1670 (C=O), 1660 (C=O), 1599 (C=N), 1560 
(C=C); 1HNMR (DMSO-d6, 300 MHz) d: 3.82 (s, 3H, OCH3), 7.27-8.51 (m, 
8H, Ar-H), 11.89 (s, 1H, NH, exchangeable with D2O), 12.28 (s, 1H, NH 
exchangeable with D2O), 12.30 (s, br, 1H, OH exchangeable with D2O); 
m/z (%): 370.1 (0.21) (M+), 221 (90.81), 178 (100); Elemental analysis 
(%): Calcd. for C17H14N4O4S (370.38): C, 55.13; H, 3.81; N, 15.13, Found 
C, 55.26; H, 3.87; N, 15.26.
Synthesis of N’-(4-chlorobenzoyl)-2-hydroxy-6-(thiophen-2-yl)-
pyrimidine-4-carbohydrazide (6c)
Yield 82%; m.p. 308-310°C, IR (KBr; cm–1): 3449 (OH), 3365 (NH), 
3199 (NH), 3035 (CH aromatic), 1652 (2 C=O), 1601 (C=N), 1555 
(C=C);1HNMR (DMSO-d6, 300 MHz) d: 7.27-8.16 (m, 8H, Ar-H), 10.60 
(s, 1H, NH exchangeable with D2O.), 10.83 (s, 1H, NH exchangeable with 
D2O), 12.30 (s, 1H, OH exchangeable with D2O); Elemental analysis (%): 
Calcd for C16H11ClN4O3S (374.80): C, 51.27; H, 2.96; N, 14.95, Found C, 
51.41; H, 2.94; N, 15.09.
General procedure for synthesis of (7 a-f)
Phosphorus oxychloride (5 ml) was added to the appropriate aromatic 
acid derivatives (2 mmol) and compound 4 (0.47 g, 2 mmol); the mixture 
was heated under reflux for 6 hrs. Excess phosphorus oxychloride was 
distilled under reduced pressure then the residue was quenched in 
ice. Sodium carbonate was added until neutral to litmus paper, and the 
separated solid was filtered and crystallized from DMF as brown crystals.
Synthesis of 4-(5-phenyl-1,3,4-oxadiazol-2-yl)-6-(thiophen-2-yl)
pyrimidin-2-ol (7a)
Yield 86%; m.p. 225-227°C; IR (KBr; cm–1): 3447 (OH), 3095 (CH 
aromatic), 1620 (C=N), 1587 (C=C);1HNMR (DMSO-d6, 300 MHz) 
d: 7.29-8.45 (m, 9H, Ar-H), 11.11 (s, 1H, OH exchangeable with D2O); 
m/z (%): 322.05 (2.11) (M+), 254 (9.62), 134.05 (100); Elemental 
analysis (%): Calcd For C16H10N4O2S (322.05): C, 59.62; H, 3.13; N, 
17.38, Found C, 59.87; H, 3.19; N, 17.56.
Synthesis of 4-(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)-6-
(thiophen-2-yl) pyrimidin-2-ol (7b)
Yield 85%; m.p. 250-252°C; IR (KBr; cm–1): 3447 (OH), 3006 (CH 
aromatic), 2962, 2932, 2837 (CH aliphatic), 1637 (C=N), 1510 (C=C); 
1HNMR (DMSO-d6) d: 3.86 (s, 3H, OCH3), 7.06-8.62 (m, 8H, Ar-H), 11.87 
(s, 1H, OH exchangeable with D2O); Elemental analysis (%): Calcd. for 




Yield 81%; m.p. 230-232°C; IR (KBr; cm–1): 3447 (OH), 3095 
(CH aromatic), 1595 (C=N), 1543 (C=C);1HNMR (DMSO-d6, 300 MHz) 
d: 7.22-8.18 (m, 8H, Ar-H), 11.04 (s, 1H, OH exchangeable with D2O); 
Elemental analysis (%): Calcd for C16H9ClN4O2S (356.79): C, 53.86; H, 
2.54; N, 15.70, Found C, 53.98; H, 2.58; N, 15.87.
Synthesis of 4-(5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl)-6-
(thiophen-2-yl)pyrimidin-2-ol (7d)
Yield 86%; m.p. 220-222°C, IR (KBr; cm–1): 3423 (OH), 3099 
(CH aromatic), 1610 (C=N) 1588 (C=C), 1523, 1345 (NO2);1HNMR 
(DMSO-d6, 300 MHz) d: 7.28-8.50 (m, 8H, Ar-H), 11.04 (s, 1H, OH, 
exchangeable with D2O); elemental analysis (%): Calcd. for C16H9N5O4S 
(367.34): C, 52.31; H, 2.47; N, 19.07, found: C, 52.49; H, 2.44; N, 19.29.
Synthesis of 4-(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)-6-(thiophen-
2-yl)pyrimidin-2-ol (7e)
Yield 83%; m.p. 294-296°C; IR (KBr; cm–1): 3419 (OH), 3095 (CH 
aromatic), 1580 (C=N), 1530 (C=C);1HNMR (DMSO-d6, 300 MHz) 
d: 7.29-8.85 (m, 7H, Ar-H), 9.39 (s, 1H, CH=N pyridine), 11.33 (s, 1H, OH 
exchangeable with D2O); Elemental analysis (%): Calcd. for C15H9N5O2S 
(323.33): C, 55.72; H, 2.81; N, 21.66, Found: C, 55.79; H, 2.79; N, 21.92.
Synthesis of 4-(5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl)-6-(thiophen-
2-yl)pyrimidin-2-ol (7f)
Yield (80%); m.p. 288-290°C; IR (KBr; cm–1): 3448 (OH), 3095 (CH 
aromatic), 1636 (C=N), 1586 (C=C); 1HNMR (DMSO-d6, 300 MHz) 
d: 7.29-8.82 (m, 8H, Ar-H), 10.57 (s, 1H, OH exchangeable with D2O); 
m/z (%): 323.30 (0.17), 264 (10.48 ), 63.95 (100); elemental analysis 
(%): Calcd. for C15H9N5O2S (323.33): C, 55.72; H, 2.81; N, 21.66, Found: 
C, 55.86; H, 2.80; N, 21.78.
Synthesis of N-(4-bromophenyl)-2-(2-hydroxy-6-(thiophen-2-yl)
pyrimidine-4-carbonyl) hydrazinecarbothioamide (8d)
A mixture of compound 4 (0.94 g, 4 mmol) and p-bromophenyl 
isothiocyanate (0.9 g, 4 mmol) in glacial acetic acid (15 ml) was heated 
under reflux for 7 hrs. The reaction mixture was diluted with ice cold 
water. The separated solid was filtered and crystallized from DMF as 
shiny yellow crystals.
Yield (82%); m.p. 225-227°C; IR (KBr; cm–1): 3448 (OH), 3314 (NH), 3195 
(NH), 3097 (CH Aromatic), 1668 (C=O) 1641 (C=N), 1594 (C=C), 1236 
(C=S); 1HNMR (DMSO-d6, 300 MHz) d: 7.27-8.15 (m, 8H, Ar-H), 9.96 (s, 
1H, NH exchangeable with D2O), 9.97 (s, 1H, NH exchangeable with D2O), 
10.81 (s, 1H, NH exchangeable with D2O), 12.40 (s, 1H, OH exchangeable 
with D2O); Elemental analysis (%): Calcd. for C16H12BrN5O2S2 (449.33): C, 
42.73; H, 2.67; N, 15.58, Found C, 42.74; H, 2.65; N, 15.72.
General method for synthesis of compounds (9a-c)
A mixture of compound 4 (0.94 g, 4 mmol) and substituted isothiocyanate 
(4 mmol) in glacial acetic acid (15 ml) was heated under reflux for 7 hrs. 
After cooling, the reaction mixture was quenched with ice. The separated 
solid was filtered and crystallized from DMF as yellow crystals.
Synthesis of 3-[2-hydroxy-6-(thiophen-2-yl)pyrimidin-4-yl]-4-
phenyl-1H-1,2,4-triazole-5(4H)-thione (9a)
Yield (91%); m.p. 255-257°C; IR (KBr; cm–1): 3447 (OH), 3250 (NH), 
3096 (CH aromatic), 1631 (C=N), 1526 (C=C), 1268 (C=S); 1HNMR 
(DMSO-d6, 300 MHz) d: 7.21-8.18 (m, 9H, Ar-H), 12.17 (s, 1H, OH 
exchangeable with D2O), 14.46 (s, 1H, NH, exchangeable with D2O); m/z 
(%): 353.05 (43.83), 134 (86.42), 77 (100); Elemental analysis (%): 
Calcd. for C16H11N5OS2 (353.42): C,54.37; H, 3.14; N, 19.82, Found: C, 
54.49; H, 3.19; N, 20.01.
Synthesis of 3-[2-hydroxy-6-(thiophen-2-yl)pyrimidin-4-yl]-4-(4-
methoxyphenyl)-1H-1,2,4-triazole-5(4H)-thione (9b)
Yield (87%); m.p. 320-322°C; IR (KBr; cm–1): 3438 (OH), 3271 (NH), 
3062 (CH aromatic), 2958, 2931, 2833 (CH aliphatic), 1626 (C=N), 
1536 (C=C), 1248 (C=S); 1HNMR (DMSO-d6, 300 MHz) d: 3.80 (s, 3H, 
OCH3), 7.02-7.88 (m, 8H, Ar-H), 12.15 (s, 1H, OH exchangeable with 
D2O), 14.22 (s, 1H, NH exchangeable with D2O); 13CNMR (DMSO-75 
MHz): 55.42, 104.54, 114.23, 126.76, 129.01, 129.54, 129.96, 132.56, 
140.25, 146.98, 159.57, 161.52, 169.66, 172.01; m/z (%): 383 (100%); 
Elemental analysis (%): Calcd. for C17H13N5O2S2 (383.45): C,53.25; H, 
3.42; N, 18.26, Found: C, 53.48; H, 3.46; N, 18.40.
Synthesis of 4-allyl-3-[2-hydroxy-6-(thiophen-2-yl)pyrimidin-4-
yl]-1H-1,2,4-triazole-5(4H)-thoine (9c)
Yield (89%); m.p. 260-262°C; IR (KBr; cm−1): 3447 (OH), 3320 (NH), 
3093 (CH aromatic), 2921 (CH aliphatic), 1603 (C=N), 1560 (C=C), 
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1247(C=S);1HNMR (DMSO-d6, 300 MHz) d: 4.99-5.04 (m, 2H, NCH2), 
5.10-5.22 (m, 2H, =CH2), 5.88-5.99 (m, 1H, =CH), 7.24-8.15 (m, 4H, Ar-H), 
12.30 (s, 1H, OH, exchangeable with D2O), 14.39 (s, 1H, NH exchangeable 
with D2O); Elemental analysis (%): Calcd. for C13H11N5OS2 (317.39): C, 




Methyl iodide (1 ml) was added to a mixture of compound 9b (0.38 g, 
1 mmol) and K2CO3 (0.3 g, 2 mmol) in DMF (10 ml). The reaction 
mixture was stirred at room temperature for 8 hrs then diluted with 
water, filtered and crystallized from DMF as pale yellow crystals.
Yield (89%); m.p. 260-262°C; IR (KBr; cm–1): 3076 (CH aromatic), 2996, 
2928, 2838 (CH aliphatic), 1666 (C=O), 1597 (C=N), 1541 (C=C), 1243 
(C=S);1HNMR (DMSO-d6, 300 MHz) d: 2.66 (s, 3H, N-CH3 triazole), 3.81 
(s, 3H, N-CH3 pyrimidine), 3.97 (s, 3H, OCH3), 6,87-8.14 (m, 8H, Ar-H); 
m/z (%): 411.30 (9.19), 395.00 (9.80), 134.00 (100); Elemental analysis 
(%): Calcd. for C19H17N5O2S2 (411.50): C, 55.46; H, 4.16; N, 17.02, Found: 
C, 55.79; H, 4.19; N, 17.14.
Synthesis of 4-(4-bromophenyl)-[2-hydroxy-6-(thiophen-2-yl)
pyrimidin-4-yl]-1H-1,2,4-triazole-5(4H)-thione (11)
Compound 8d (0.45 g, 1 mmol.) was refluxed for 8 hrs in 2N sodium 
hydroxide (10 ml). The reaction mixture was then quenched with ice, 
acidified to litmus paper with glacial acetic acid, filtered. The separated 
product was crystallized from DMF as brown crystals.
Yield (82%); m.p. 233-235°C; IR (KBr; cm−1): 3453 (OH), 3294 
(NH-triazole), 3092 (CH aromatic), 1628(C=N), 1559 (C=C), 1345 
(C=S);1HNMR (DMSO-d6, 300 MHz) d: 7.23-9.11 (m, 8H, Ar-H), 11.12 
(s, 1H, OH exchangeable with D2O), 14.5 (s, 1H, NH exchangeable with 
D2O); m/z (%): 433 (M+2) (11.65), 431 (M+) (11.70), 134.05 (100); 
Elemental analysis (%): Calcd. for C16H10BrN5OS2 (431.32): C, 44.54; H, 
2.32; N, 16.24. Found C, 44.53; H, 2.30, N, 16.42.
Synthesis of [5-(4-bromophenylamino)-1,3,4-thiadiazol-2-yl]-4-
(thiophen-2-yl) pyrimidin-2(1H)-one (12)
To compound 8 d (0.45 g, 1 mmol), ice cold concentrated sulfuric 
acid (6 ml) was added drop wise while stirring. The reaction mixture 
was left for 24 hrs, quenched with ice and treated with concentrated 
ammonia solution until neutral to litmus paper. The separated solid 
was washed with water, filtered, dried and crystallized from ethanol as 
brown crystals
Yield (85%); m.p. 315-317°C; IR (KBr; cm−1): 3169 (br, 2NH), 3033 
(CH aromatic), 2935 (CH aliphatic), 1660 (C=O), 1634 (C=N), 1597 
(C=C); 1HNMR (DMSO-d6, 300 MHz) d: 7.26-8.16 (m, 8H, Ar-H), 
10.03 (br, s, 2H, 2 NH exchangeable with D2O); m/z (%): 433 (M+2) 
(9.72), 431 (M+) (9.72), 46 (100); elemental analysis (%): Calcd. for 
C16H10BrN5OS2 (431.32): C, 44.54; H, 2.32; N, 16.24. Found: C, 44.71; H, 
2.31; N, 16.39.
In vitro cytotoxic activity
Potential cytotoxicity of the newly obtained derivatives was tested 
using the method of Skehan et al. [37]. Cells were plated in the 
96-multiwell plate (5 × 103cells/well) for 24 hrs before treatment 
with the compounds to allow attachment of cell to the wall of the 
plate. Different concentrations of the tested compounds (0, 5, 12.5, 
25 and 50 µg/ml) were added to the cell monolayer triplicate wells 
prepared for each individual dose. Monolayer cells were incubated 
with the compounds for 48 hrs at 37°C under a 5% CO2 atmosphere. 
The culture was fixed with cold trichloroacetic acid and stained with 
0.4% Sulforhodamine-B stain dissolved in 1% acetic acid. Excess stain 
was washed with acetic acid and attached stain was recovered with 
tris ethylenediaminetetraacetic acid buffer and the color intensity was 
measured in an ELISA reader. The relation between surviving fraction 
and drug concentration is plotted to get the survival curve of each 
tumor cell line of the specified compound. IC50 values were calculated 
from the calibration curve and illustrated in Table 1.
Antimicrobial activity
Antibacterial activity
The newly synthesized compounds were tested for their 
in vitro antibacterial activity, in comparison to Cefotaxime and 
sulfamethoxazole as reference drugs using the standard agar cup 
diffusion method [38-42]. Bacterial strains were individually cultured 
for 48 hrs in 100 ml conical flasks containing 30 ml nutrient agar. The 
assay was done in 10 cm sterile petri dishes into which a bacterial 
suspension (1 ml) in nutrient agar (15 ml) was poured. Plates were 
shaken gently to homogenize the contents. After solidification of the 
media, 5 mm cavities were cut in the solidified agar (4 cavities/plate) 
using sterile cork borer. The test compounds and the reference drugs 
were dissolved in DMF (100 µmol/ml) and were pipette in the cavities. 
In addition, other cavities were pipette with DMF and served as a 
negative control. The seeded plates were incubated at 28±2°C for 
48 hrs. The radii of inhibition zones (in mm) of triplicate sets were 
measured and the results are cited in Table 2.
Antifungal activity
The test compounds were evaluated for their antifungal activity in vitro, 
in comparison to Nystatin as a reference drug using the agar cup 
diffusion method [38-42] against two fungal strains: Aspergillus niger 
(ATCC 16404) and Candida albicans (ATCC 10231). Spore suspensions 
in sterile distilled water were prepared from 7-day-old culture of 
the test fungi growing on Sabouraud’s dextrose broth (30 ml) media 
in 100 ml conical flasks. The final spore concentration was nearly 
5 × 104 spores/ml. About 15 ml of the growth medium was introduced 
on sterilized Petri dishes of 10 cm diameter and inoculated with 1 ml 
of spore suspension. Plates were shaken gently to homogenize the 
inocula. After solidification of the media, 5 mm cavities were cut in the 
solidified agar (4 cavities/plate) using sterile cork borer and was filled 
with the solutions of the test compounds and Nystatin (100 µmol/ml in 
DMF). In addition, other cavities were impregnated with solvent (DMF) 
and served as a negative control. The seeded plates were incubated at 
28±2°C for 7 days. The radii of inhibition zones (in mm) of triplicate 
sets were measured at successive intervals during the incubation 
period, and the results are cited in Table 2.
RESULTS AND DISCUSSION
Chemistry
The novel pyrimidine derivatives were prepared as outlined in 
schemes 1-4.
The intermediate 1 was prepared as previously reported method [36] 























a=IC50 is a dose required to inhibit the cell growth by 50% (values are the 
mean±SD of three separate experiments), NAb: No activity (i.e., IC50 values are 
higher than 50 μg/ml), SD: Standard deviation
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This new compound was stirred with methyl or butyl iodide in DMF 
containing K2CO3 at room temperature to give compounds 3a,b. On the 
other hand, refluxing compound 2 with hydrazine hydrate in ethanol 
for 5 hrs afforded 2-oxo-6-(thiophen-2-yl)-2,3-dihydropyrimidine-4-
carbohydrazide (4).
Moreover, new hydrazone derivatives 5a-g were synthesized in 
moderate to high yields through condensation of the acid hydrazide 
4 with different aromatic aldehydes in acetic acid under reflux 
(Scheme 1).
In an attempt to synthesize the oxadiazole derivatives 7a-c using 
benzoyl chloride or substituted benzoyl chloride (p-Cl, p-OCH3) and the 
hydrazide 4 in pyridine under reflux, only the N-benzoylated compounds 
6a-c were achieved. The structure of compounds 6a-c was characterized 
using spectroscopic and elemental analysis. IR spectroscopy showed 
the presence of two NH bands at 3371-3109 cm−1 and two carbonyl 
bands at 1660-1652 cm−1 range indicating open chain structure. 
Furthermore, 1HNMR spectra verified the structure by the appearance 
of two exchangeable NH signals at 10.60-12.30 ppm range. On the other 
hand, the desired oxadiazole derivatives 7a-f were obtained through 
the reaction of the acid hydrazide 4 with aromatic acid derivatives 
in phosphorous oxychloride at reflux temperature. The structure 
of the oxadiazoles 7a-f was verified using elemental analysis and 
spectroscopic data. Structure elucidation of the oxadiazole 7b can be 
done chemically through the cyclodehydration of compound 6b using 
phosphorous oxychloride under reflux for only 4 hrs (Scheme 2).
It was reported that reaction of the hydrazide derivatives with 
different substituted isothiocyanates lead to N-substituted 
thiosmicarbazides [43].  In our work, substituted isothiocyanates 
reacted with the hydrazide 4 differently. When phenyl, p-methoxy 
phenyl or allyl isothicyanate was used, the unexpected 3-[2-hydroxy-6-
(thiophen-2-yl)pyrimidin-4-yl]-4-substituted-1H-1,2,4-triazole-5(4H)-
thione (9a-c) were obtained instead of the desired thiosemicarbazide 
derivatives (8a-c). The structure of the obtained products was 
confirmed using elemental analysis, spectroscopic data as well as 
chemical reaction. IR spectroscopy provided only two NH bands at 
3447-3421 cm–1 and 3344-3250 cm–1 ranges. Moreover, C=S band 
appeared at 1268-1247 cm–1 range and only one carbonyl band 
appeared. In addition,1HNMR showed two NH signals at position 12.24 
and 14.03 ppm. Structure elucidation of compounds 9a-c was carried 
out using methylation reaction. Compound 9b was reacted with excess 
methyl iodide in DMF containing potassium carbonate anhydrous at 
room temperature to give dimethylated compound 10 indicating the 
cyclic structure of compounds 9a-c (Scheme 3).
Furthermore, the target thiosemicarbazide derivative 8d was obtained 
only when the hydrazide 4 reacted with p-bromophenyl isothiocyanate 
in refluxing acetic acid for 7 hrs. The structure of compound 8d 
Table 2: The antimicrobial activity
Sample 
no.
Diameter (mm) of inhibition zones against the corresponding standard strains of different microorganisms




























2 40 41 40 13 11 12 12 41 42
3a 30 29 31 - - - - - -
3b - - - - - - - 36 35
4 39 40 40 13 14 13 13 35 34
5a 20 21 20 15 14 13 14 26 25
5b 22 23 21 16 17 15 16 24 23
5c 42 41 43 32 33 31 32 43 42
5d 20 21 20 22 23 21 22 31 32
5e 39 40 39 21 22 21 21 - -
5f 23 22 23 - - - - - -
5g 22 21 23 21 20 21 20 13 12
6a 15 14 16 25 26 24 25 24 23
6b - - - 29 28 28 28 - -
6c 20 21 20 25 26 24 25 23 22
7a 20 19 21 21 22 21 21 29 28
7b 12 13 12 20 21 19 20 31 32
7c 16 17 16 23 24 22 23 26 25
7d 15 16 15 25 26 24 25 24 23
7e 21 22 20 - - - - 24 23
7f 23 24 22 - - - - 40 39
8d 34 35 34 26 27 25 26 40 39
9a 36 37 36 25 26 24 25 30 28
9b 29 30 28 25 24 23 24 34 33
9c 32 31 33 20 19 21 20 30 29
11 29 30 29 25 25 26 25 26 25
12 38 39 38 26 27 27 26 - -
Cefotaxime 
(control)




25 23 30 25 27 28 30 - -
Nystatin 
(control)
- - - - - - - 25 20
DMF 
(control)
- - - - - - - - -
The method used is agar cup diffusion method, each cup is filled with 100 ml from each sample, Conc. of each sample is 5 mg/ml, Conc. of antimicrobial agents is 
5 mg/ml, DMF: Dimethyl formamide
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was proved using spectroscopic data and elemental analysis. IR 
spectroscopy showed the presence of 3NH bands at 3448, 3314 and 
3195 cm–1. Furthermore, the presence of carbonyl band at 1668 cm–1 
indicated the open chain structure. On the other hand, 1HNMR showed 
four exchangeable signals appeared at 9.96, 9.97, 10.81 ppm referred 
to three NH of the open chain structure and 12.40 ppm for one OH of 
the pyrimidine ring. The structure of compound 8d was also evidenced 
by its reaction with either 2N NaOH or cold conc. sulfuric acid to give 
4-(4-bromophenyl)-3-(2-hydroxy-6-(thiophen-2-yl)pyrimidin-4-yl)-
1H-1,2,4-triazole-5(4H)-thione (11) and 6-(5-(4-bromophenylamino)-
1,3,4-thiadiazol-2-yl)4-(thiophen-2-yl)pyrimidin-2-(1H)-one (12) 
respectively. The new heterocyclic compounds 11 and 12 were 
subjected to spectroscopic and elemental analysis to verify their 
structures (Scheme 4).
In vitro cytotoxic activity
From the newly synthesized compounds, only ten compounds 4, 5b, 
5c, 5f, 6b, 7b, 8d, 9b, 11 and 12 were selected to be evaluated for their 
cytotoxicity against human breast carcinoma (MCF7) cell line and 
colon carcinoma (HCT116) cell line using Skehan et al. method [37]. 
The inhibitory activities were presented as micromolar concentrations 
of the compound that cause 50% inhibition per unit of enzyme (IC50) 
under the assay condition. Results of cancer cellular assays are shown 
in Table 1. By investigating the variation in selectivity of the tested 
compounds over the cell lines, it was noticed that, acid hydrazide 4 has 
moderate activity against breast carcinoma cell line (IC5o=33.7 μg/ml) 
but it is devoid of cytotoxic activity against colon carcinoma cell line. By 
its condensation with different aromatic aldehydes to give hydrazone 
derivatives, their cytotoxic activity were reduced against breast 
carcinoma cell line and showed certain activities against colon 
Scheme 1: Synthesis of target compounds 1-5
Scheme 2: Synthesis of target compounds 6, 7
Scheme 3: Synthesis of target compounds 9, 10
Scheme 4: Synthesis of target compounds 8d, 11 and 12
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carcinoma cell line for compounds 5b and 5f. However, compound 5c 
showed only activity against breast cancer cell line.
Acylation of acid hydrazide 4 using p-methoxybenzoyl chloride afforded 
compound 6b which has moderate activity against colon carcinoma cell 
line (IC50=24 μg/ml) and breast carcinoma cell line (IC50=30.3 μg/ml).
Cyclization of compound 6b using phosphorous oxychloride afforded 
the most active oxadiazole derivative 7b against breast carcinoma 
cell lines (IC50 =7.6 μg/ml). On the other hand, the [1,2,4]-triazole-5-
thione derivative 9b which was obtained from direct cyclization of 
the acid hydrazide 4 using p-methoxyphenyl isothiocyanate, showed 
weak activity against colon carcinoma cell line and no activity against 
breast carcinoma cell line. However, the [1,2,4]-triazole-5-thione 
derivative 11 which was obtained from cyclization of the totally inactive 
thiosmicarbazide 8d was the most active cytotoxic compound against 
colon cancer cells, even more powerful than the standard drug. Finally, 
cyclization of compound 8d to 1,3,4–thiadiazole derivative 12 did not 
change cytotoxic activity against both cell lines.
Preliminary antimicrobial screening
All of the newly synthesized compounds were screened for their 
antimicrobial activity using cup plate diffusion method [38-42].
Staphylococcus aureus (ATCC 6538), Staphylococcus epidermidis (ATCC 
12228) and Micrococcus spp. (ATCC 10240) were be used as Gram-
positive bacterial strains. However, Pseudomonas aeruginosa (ATCC 
9027), Klebsiella pneumonia (ATCC 27736), Salmonella typhimurium 
(ATCC 14028), and Escherichia coli (ATCC 10536) were be used 
as Gram-negative bacterial strains. In addition, two fungi strains, 
including A. niger (ATCC 16404) and C. albicans (ATCC 10231) were 
be used in this evaluation. The results were reported as zone of 
inhibition compared to standard Cefotaxime and Sulphamethoxazole 
as antibacterial drugs and Nystatin as antifungal drug. The results 
illustrated in Table 2 revealed that many of the tested compounds were 
found to exhibit good to excellent antimicrobial activity. It was observed 
that, the most active compound against both bacterial and fungal 
strains was the hydrazone derivative 5c. However, compounds 2 and 4 
showed high activity against Gram-positive strains, fungal strains and 
weak activity against Gram-negative strains. Alkylation of compound 2 
to give compound 3a and 3b, lead to only anti-Gram-positive activity 
for compound 3a and antifungal activity for compound 3b indicating 
the importance of NH in pyrimidine ring for broad spectrum activity. 
On the other hand, the hydrazone derivatives 5a-g, except compound 
5c and 5f, showed moderate antimicrobial activity. N-benzylation 
of the hydrazide 4 declined both anti-Gram-positive and antifungal 
activities; however, anti-Gram-negative activity enhanced. Compounds 
7 a-f exhibited variable antimicrobial activity. The phenylsubstituted 
oxadiazoles 7 a-d, showed moderate antimicrobial activity. However, the 
pyridylsubstituted oxadiazoles 7 e, f showed only anti-Gram-positive 
and antifungal activities. The thiosemithiocarbazide 8d represented 
potent antimicrobial compound. Cyclization of compound 8d gave 
the less potent [1,2,4]triazole derivative 11 as anti-Gram-positive 
and antifungal compound. However, 1,3,4-thiadiazole 12 devoid of 
antifungal activity. On the other hand, [1,2,4]triazoles 9a-c showed high 
potency against Gram-positive and fungal strains in comparison with 
the [1,2,4] triazole derivative 11.
CONCLUSION
In the present work, a new class of pyrimidine derivatives was 
obtained starting from the hydrazide 4. This hydrazide was utilized 
in the synthesis of several hydrazones, oxadiazoles, triazoles, and 
a thiadiazole derivative. The newly synthesized heterocycles were 
evaluated for their anticancer and antimicrobial properties. The most 
potent cytotoxic compounds were oxadiazole 7b and the [1,2,4]triazole 
11. Accordingly, we can conclude that incorporation of five-member 
heterocyclic rings with the pyrimidine moiety is important for cytotoxic 
activity. Considering antimicrobial activity, we observed that most of 
the targets exhibited broad spectrum activity. However, compounds 2, 
4, 5c, and 8d represented the most potent ones. These results suggested 
that pyrimidine moiety linked to several chains and other heterocycles 
is interesting molecules for further synthesis and biological evaluation.
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